WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Gormez, Selcuk

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study
    (SPRINGERNATURE, 2021-01-01) Gormez, Selcuk; Ekicibasi, Erkan; Degirmencioglu, Aleks; Paudel, Ashok; Erdim, Refik; Gumusel, Hilal Kurtoglu; Eroglu, Elif; Tanboga, Ibrahim Halil; Dagdelen, Sinan; Sariguzel, Nevin; Kirisoglu, Ceyda Erel; Pamukcu, Burak
    The aim of this study was to investigate the possible relationship between worse clinical outcomes and the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in hospitalized COVID-19 patients. A total of 247 adult patients (154 males, 93 females
  • Thumbnail Image
    Item
    Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
    (AVES, 2021-01-01) Gormez, Selcuk; Kirisoglu, Ceyda Erel; Ekicibasi, Mehmet Erkan; Degirmencioglu, Aleks; Paudel, Ashok; Akan, Gokce; Atalar, Fatmahan; Sariguzel, Nevin; Pamukcu, Burak
    Objective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias. Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups. Results: A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with non-COVID-19 viral pneumonia than in patients with COVID-19 (39.6\% vs 22.3\%, respectively, p=0.012 and 24.2\% vs 4.9\%, respectively, p<0.001). In our study, 2.9\% and 6.8\% of patients with COVID-19 were on ACEIs and ARBs, respectively, whereas 13.2\% and 19.8\% of patients with non-COVID-19 viral pneumonia were on ACEIs and ARBs, respectively (p=0.009 and p=0.013). Neutrophil-to-lymphocyte ratio (p<0.001) was prominent in patients with non-COVID-19 viral pneumonia compared with patients with COVID-19. Conclusion: Our study results indicate that hypertension and CAD are more common among patients with non-COVID-19 viral pneumonia than patients with COVID-19. The prevalence of ACEIs and ARBs use was not higher in patients with COVID-19. Our results support that the use of ACEIs and ARBs do not play a specific role in patients with COVID-19.
  • No Thumbnail Available
    Item
    Comparison of early and long-term follow-up results of percutaneous mitral balloon valvuloplasty and mitral valve replacement
    (ASSOC MEDICA BRASILEIRA, 2021-01-01) Usta, Emrah; Erdim, Refik; Gormez, Selcuk; Dogan, Ali; Ezelsoy, Mehmet; Kahraman, Serkan; Bayram, Muhammed; Yazicioglu, Nuran
    BACKGROUND: Percutaneous mitral balloon valvuloplasty and mitral valve replacement have been the treatment options for mitral stenosis for several years, however, studies that compare these two modalities are very rare in the literature. ObjectIve: In this article, we aim to investigate the comparison of clinical results of percutaneous mitral balloon valvuloplasty and mitral valve replacement. Methods: 527 patients with rheumatic mitral stenosis, treated with percutaneous mitral balloon valvuloplasty or mitral valve replacement (276 patients with percutaneous mitral balloon valvuloplasty and 251 patients with mitral valve replacement) from 1991 to 2012 were evaluated. The demographic characteristics, clinical, echocardiographic and catheterization data of patients were evaluated retrospectively. The results of early and late clinical follow-up of patients after percutaneous mitral balloon valvuloplasty and mitral valve replacement were also evaluated. Results: The mean follow-up time of the percutaneous mitral balloon valvuloplasty group was 4.7 years and, for the mitral valve replacement-group, it was 5.45 years. The hospital stay of the percutaneous mitral balloon valvuloplasty group was shorter than that of the mitral valve replacement group (2.02 days vs 10.62 days, p<0.001). The hospital mortality rate of percutaneous mitral balloon valvuloplasty and mitral valve replacement were 0\% and 2\% respectively (p=0.024). In the percutaneous mitral balloon valvuloplasty group, early postprocedural success rate was 92.1\%. The event-free survival of percutaneous mitral balloon valvuloplasty and mitral valve replacement was found to be similar. While reintervention was higher in percutaneous mitral balloon valvuloplasty-group (p<0.001), mortality rate was higher in mitral valve replacement-group (p<0.001). Conclusion: Percutaneous mitral balloon valvuloplasty seems to be more advantageous than mitral valve replacement due to low mortality rates, easy application of the procedure and no need for general anesthesia.